Performance Comparison of the Illumina MiSeq i100 with Established Instruments for Amplicon-Based Somatic and Liquid Biopsy Sequencing Panels
Pillar benchmarked seven oncoReveal® amplicon NGS panels — BRCA1/BRCA2 Somatic with CNV, Multi-Cancer v4 with CNV, Myeloid, Essential MPN, Nexus 21 Gene, Rapid AML, and Essential LBx — on Illumina’s new MiSeq i100 against the legacy MiSeq and NextSeq 550. Fifty-nine paired samples, including SeraCare and Horizon Discovery reference standards, cancer cell line DNA, and biobanked clinical specimens, were run from identical libraries across six sequencing runs. Every expected true-positive variant was detected on the i100 with no false positives, confirming that the portfolio transfers cleanly to the new platform.
Detecting Ultra-Low Frequency ESR1 Mutations in Liquid Biopsy Samples Using the oncoReveal Essential LBx Panel
The oncoReveal® Essential LBx Panel is a single-tube, 34-gene amplicon-based NGS liquid biopsy assay built on SLIMamp® chemistry. Pillar tested it on Seraseq® ctDNA ESR1 reference standards diluted to 0.05% variant allele frequency (VAF) from 5–30 ng of plasma cell-free DNA (cfDNA), sequenced on the Illumina NextSeq 550 and analyzed with PiVAT® software. It detected these endocrine-therapy-resistance mutations in HR-positive breast cancer with 98.4% PPA at 0.1% VAF and 100% NPA — no molecular barcodes (UMIs) required.
Detecting Contamination in Cell-free DNA Sequencing Libraries using Germline Markers
Pillar developed a panel-agnostic Bayesian method to detect sample-to-sample contamination within cell-free DNA (cfDNA) sequencing batches, where variant allele fractions below 0.5% make false positive calls especially costly. The algorithm genotypes germline single nucleotide polymorphisms (SNPs) across a batch, flags sites with discordant allele fractions, and computes the posterior probability that observed read counts reflect contamination rather than stochastic noise. Across in silico mixes, contrived cell line mixes, and CNV-positive tumor samples it detected contamination down to 1% using 30 homozygous SNPs while holding 99–100% specificity.
Streamlined and Accurate Detection of Actionable Fusions with the oncoReveal Multi-Cancer RNA Fusion v2 Panel
Atrium Health and CPG Pathology compared Pillar’s oncoReveal® Multi-Cancer RNA Fusion v2 panel against Archer’s FUSIONPlex Pan Solid Tumor v2 for detecting actionable gene fusions in lung and other solid tumors. RNA from 96 fusion-positive specimens — lung, liver, lymph node, brain, sarcoma, pleural and pericardial fluid — was prepared per protocol and sequenced on the Illumina NextSeq 550 Dx with PiVAT® analysis. Pillar detected 82 of 82 covered fusions, fully concordant with Archer, at roughly half the cost per test and with library preparation in 4.5 hours rather than 36.
Comparative Performance of Targeted and Comprehensive Somatic NGS Panels in Paired Tumor and Liquid Biopsy Samples from a Prospective Solid Tumor Cohort
Eurofins Viracor Biopharma, with Illumina and Pillar, prospectively enrolled 61 patients with advanced solid tumors and tested matched FFPE tissue and plasma using Pillar’s amplicon panels (oncoReveal® Multi-Cancer, 60 genes, tissue; Core LBx, 104 genes, ctDNA) alongside Illumina’s TSO500 hybrid-capture panels (523 genes). The comprehensive panel showed higher tissue–plasma concordance, largely because its gene content is harmonized across specimen types while the Pillar tissue and liquid biopsy panels target different gene sets. Even so, 58.0% of Pillar’s concordant calls were clinically significant Tier I/II variants — the highest such proportion in the study.
Race Against the Clock: Validating a Rapid NGS Myeloid Panel
The Hospital of the University of Pennsylvania built its Hematological Expedited Sequencing (HEXS) assay on Pillar’s oncoReveal® Myeloid Panel, consolidating 58 myeloid neoplasm genes into a single NGS test to replace multiple send-outs for acute leukemia subtyping. Validation used 61 positive and 18 negative bone marrow, peripheral blood, and bone core specimens covering SNVs, indels, and FLT3 internal tandem duplications, on both the MiSeq and MiSeq i100 with PiVAT® variant calling. HEXS reached 99.5–100% sensitivity across variant types and enables 3–5 day myeloid NGS reporting, with the i100 cutting sequencing time by 17 hours.
Evaluation of oncoReveal Essential MPN Panel on Illumina MiSeq i100 for Key Driver Mutation Testing in Myeloproliferative Neoplasms
Mayo Clinic’s Molecular Hematopathology Laboratory evaluated Pillar’s oncoReveal® Essential MPN Panel — a single-tube SLIMamp® amplicon NGS assay targeting JAK2, CALR, and MPL — on the Illumina MiSeq i100 for BCR::ABL1-negative myeloproliferative neoplasm (MPN) testing. Ninety-four peripheral blood and bone marrow specimens were compared against the laboratory’s capture-based myeloid NGS panel, JAK2 V617F allele-specific PCR, CALR fragment analysis, and MPL Sanger sequencing. The panel showed 91–100% concordance across comparators and returned results within 24 hours of extraction, against 5–7 days for the conventional reflex cascade.
Analytical Concordance of NGS-based Tests for ESR1 Mutation Detection in Plasma
Performance of Pillar oncoReveal Essential MPN Panel: experiences of two clinical diagnostic laboratories
Advocate Health ACL Laboratories and Atrium Health Molecular Pathology jointly validated Pillar’s oncoReveal® Essential MPN Panel across two laboratory sites, replacing the single-gene cascading algorithm conventionally used to test JAK2, CALR and MPL in myeloproliferative neoplasms — a workflow that lengthens turnaround, risks errors from sample splitting, and is expensive to manage. Two hundred thirty-nine clinical blood and bone marrow specimens were sequenced on Illumina MiSeq and NextSeq 550 Dx with PiVAT® reporting, and every identified variant was confirmed by an orthogonal PCR, qPCR or PCR/CE method. Concordance was 100%, repeatability and reproducibility were 100%, and average turnaround shortened by 7–10 days.
Performance of oncoReveal MLH1 & MGMT Methylation Panel from Pillar Bioscience
Advocate Health ACL Laboratories evaluated Pillar’s oncoReveal® MLH1 & MGMT Methylation Panel, a bisulfite-based NGS assay using SLIMamp® chemistry to quantify promoter CpG island methylation — the gene-silencing marker that predicts temozolomide response in glioma and supports Lynch syndrome workup. DNA from 61 MGMT and 57 MLH1 FFPE clinical samples of known methylation status was bisulfite converted, sequenced on the Illumina MiSeq, analyzed with PiVAT®, and confirmed by orthogonal MassArray or ddPCR. MLH1 correlated 100% and MGMT 95.1%, with laboratory turnaround shortened by 7–10 days versus the prior send-out process.